Sanofi partners with Moderna to help manufacture COVID-19 vaccine

April 27, 2021

Sanofi has entered into an agreement with Moderna that will have Sanofi aid in the manufacturing of Moderna´s COVID-19 vaccine.

Sanofi will tap into its established infrastructure at its site in Ridgefield, NJ, to perform fill and finish of up to 200 million doses of Moderna’s COVID-19 vaccine, starting in September.

This partnership will be Sanofi’s third commitment to provide manufacturing support. Earlier this year, Sanofi announced the company will provide support to BioNTech for 125 million doses for the European Union and in February, it said its manufacturing site in France would support Johnson & Johnson for the production of its COVID-19 vaccine at a rate of approximately 12 million doses per month. Sanofi is the only large manufacturer to support all three vaccine efforts.

Sanofi is still developing its two COVID-19 vaccine candidates

Sanofi is collaborating with GSK on a COVID-19 vaccine candidate using a recombinant protein-based manufacturing technology, combined with GSK’s established pandemic adjuvant platform.

On February 22, Sanofi and GSK announced the beginning of a Phase 2 study with an improved antigen formulation. Enrollment of total 720 participants was completed on March 8 and results are expected in Q2 2021. This vaccine is anticipated to be available in Q4 2021 pending Phase 3 outcomes and regulatory authorizations.

Sanofi is developing a messenger RNA vaccine in partnership with Translate Bio as well. In March 2021, Sanofi and Translate Bio initiated a Phase 1/2 clinical trial of their mRNA COVID-19 vaccine candidate.

Read the Sanofi statement.